Canvax Biotech
Canvax Biotech SL was founded on late 2001 to develop new technologies for antigens discovery. In 2001 the company won the CREARA 50k Start-up Business Plan Competition based on the famous MIT $50k Entrepreneurship Competition from MIT
About Us
One major strength of our company as a supplier of DNA cloning kits and reagents is that they have been developed with focus on the drawbacks of existing cloning kits: low efficiency and highly biased DNA cloning. We know that DNA cloning is no more than a tool and science is what you do with tools. But only with better tools you can deliver better science. On the other hand, working hard without the best tools will not give you the best productivity.
Canvax Biotech SL participates in several public-funded projects from MICINN and the Centre for the Development of Industrial Technology (CDTI). From late 2001 the company is participated by Global Dominion Access SA, a high technology holding of companies with over 1500 employees and a revenue of more than 400M€.
Our Areas
The company is now active in three main areas
DNA cloning kits and reagents for R&D.
High throughput protein expression for vaccines.
Novel drug discovery technologies, in particular novel HTS methods for drug discovery.
pSpark® DNA cloning technology is among the results of investments and internal R&D made by the company in the area of antigens discovery.
